Vericel (NASDAQ:VCEL) announced its earnings results on Tuesday. The biotechnology company reported $0.20 EPS for the quarter, meeting the consensus estimate of $0.20, Briefing.com reports. Vericel had a positive return on equity of 3.66% and a negative net margin of 12.68%. The business had revenue of $39.40 million during the quarter, compared to the consensus estimate of $38.99 million. During the same period in the prior year, the business posted $0.11 earnings per share. Vericel’s revenue was up 25.9% compared to the same quarter last year. Vericel updated its FY 2020
Pre-Market guidance to EPS.
VCEL opened at $16.69 on Wednesday. Vericel has a fifty-two week low of $13.40 and a fifty-two week high of $21.00. The business has a 50-day moving average of $17.48 and a 200-day moving average of $16.98. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.93 and a quick ratio of 6.48. The company has a market capitalization of $837.04 million, a PE ratio of -49.09 and a beta of 2.74.
Several brokerages recently issued reports on VCEL. Zacks Investment Research raised Vericel from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Wednesday, January 15th. BidaskClub raised Vericel from a “sell” rating to a “hold” rating in a research note on Thursday, February 13th. ValuEngine downgraded Vericel from a “buy” rating to a “hold” rating in a research note on Tuesday, January 28th. HC Wainwright increased their price objective on Vericel from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Vericel in a research note on Tuesday, November 5th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Vericel currently has an average rating of “Buy” and an average target price of $22.78.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
Featured Story: Closed-End Mutual Funds
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.